Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

307 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Alpha-fetoprotein (AFP) levels in normal children.
Ohama K, Nagase H, Ogino K, Tsuchida K, Tanaka M, Kubo M, Horita S, Kawakami K, Ohmori M. Ohama K, et al. Among authors: Horita S. Eur J Pediatr Surg. 1997 Oct;7(5):267-9. doi: 10.1055/s-2008-1071168. Eur J Pediatr Surg. 1997. PMID: 9402482
Yolk sac tumor with a unique uniform hepatoid pattern histology.
Konno A, Kudo M, Ichihara T, Yamagami M, Horita S, Ohama K, Taketa K, Koizumi S. Konno A, et al. Among authors: Horita S. Acta Paediatr Jpn. 1998 Oct;40(5):466-9. doi: 10.1111/j.1442-200x.1998.tb01970.x. Acta Paediatr Jpn. 1998. PMID: 9821708
[A case report of a 6-year-old boy with intracranial yolk sac tumor treated by VAB-6 regimen].
Wada H, Kubo M, Wada T, Ueno Y, Horita S, Ohki T, Munemoto S, Kuroda E, Taguchi H, Muramatsu N. Wada H, et al. Among authors: Horita S. No Shinkei Geka. 1995 Jan;23(1):65-8. No Shinkei Geka. 1995. PMID: 7531296 Japanese.
In this report, we describe a 6-year-old boy, Down syndrome and Hirschsprung's disease with intracranial pure yolk sac tumor treated by combined chemotherapy with cisplatin, vinblastine, bleomycin and cyclophosphamide (modified VAB-6 regimen). ...
In this report, we describe a 6-year-old boy, Down syndrome and Hirschsprung's disease with intracranial pure yolk sac tumor treated …
Maturation of the pituitary-thyroid axis during the perinatal period.
Hashimoto H, Sato T, Horita S, Kubo M, Ohki T. Hashimoto H, et al. Among authors: Horita S. Endocrinol Jpn. 1991 Apr;38(2):151-7. doi: 10.1507/endocrj1954.38.151. Endocrinol Jpn. 1991. PMID: 1752233
Membrane-type matrix metalloproteinase-1 expression and activation of gelatinase A as prognostic markers in advanced pediatric neuroblastoma.
Sakakibara M, Koizumi S, Saikawa Y, Wada H, Ichihara T, Sato H, Horita S, Mugishima H, Kaneko Y, Koike K. Sakakibara M, et al. Among authors: Horita S. Cancer. 1999 Jan 1;85(1):231-9. doi: 10.1002/(sici)1097-0142(19990101)85:1<231::aid-cncr31>3.0.co;2-3. Cancer. 1999. PMID: 9921997
A case developing minimal change disease during the course of IgG4-related disease.
Yamada K, Zoshima T, Ito K, Mizushima I, Hara S, Horita S, Nuka H, Hamano R, Fujii H, Yamagishi M, Kawano M. Yamada K, et al. Among authors: Horita S. Mod Rheumatol. 2017 Jul;27(4):712-715. doi: 10.3109/14397595.2015.1019958. Epub 2015 Mar 24. Mod Rheumatol. 2017. PMID: 25736358
The patient's serum IgG4 level did not increase and hypocomplementemia was not found. A renal biopsy showed no cellular infiltration in the renal interstitium, and no spiking or bubbling was found on periodic acid methenamine silver staining. ...
The patient's serum IgG4 level did not increase and hypocomplementemia was not found. A renal biopsy showed no cellular infiltration …
[Clinical study of fluconazole-injectable and -granules in pediatric patients].
Seki H, Seno A, Sakazume S, Shinoda K, Shintani N, Wada T, Wada H, Koizumi S, Taniguchi N, Horita S, et al. Seki H, et al. Among authors: Horita S. Jpn J Antibiot. 1994 Mar;47(3):289-95. Jpn J Antibiot. 1994. PMID: 8182900 Clinical Trial. Japanese.
A case of IgG4-related tubulointerstitial nephritis and membranous glomerulonephritis during the clinical course of gastric cancer: Imaging features of IgG4-related kidney disease.
Horita S, Fujii H, Mizushima I, Fujisawa Y, Hara S, Yamada K, Inoue D, Nakajima K, Harada K, Kawano M. Horita S, et al. Mod Rheumatol. 2019 May;29(3):542-546. doi: 10.1080/14397595.2016.1245238. Epub 2016 Oct 27. Mod Rheumatol. 2019. PMID: 27785920
Cooperative study on arterial regional chemotherapy for primary liver cancer in Hokkaido.
Kusano M, Mito M, Nakanishi M, Matsushima T, Une Y, Suga M, Sekiya C, Ishikawa Y, Horita S, Kawamura A, et al. Kusano M, et al. Among authors: Horita S. Cancer Chemother Pharmacol. 1989;23 Suppl:S17-20. doi: 10.1007/bf00647232. Cancer Chemother Pharmacol. 1989. PMID: 2924385
Studies of the oxidation states of hemoglobin M Boston and hemoglobin M Saskatoon in blood by EPR spectroscopy.
Nagai M, Mawatari K, Nagai Y, Horita S, Yoneyama Y, Hori H. Nagai M, et al. Among authors: Horita S. Biochem Biophys Res Commun. 1995 May 16;210(2):483-90. doi: 10.1006/bbrc.1995.1686. Biochem Biophys Res Commun. 1995. PMID: 7755625
The extent of the oxidation of Hemoglobin (Hb) M Saskatoon (beta 63His-->Tyr) and Hb M Boston (alpha 58His-->Tyr) in the patient's blood was determined by measurement of the intensity of EPR signals at g perpendicular = 6.0 for the normal subunits, g1 = 6.7 for the mutant subunits of Hb M Saskatoon and g1 = 6.3 for those of Hb M Boston, respectively. ...
The extent of the oxidation of Hemoglobin (Hb) M Saskatoon (beta 63His-->Tyr) and Hb M Boston (alpha 58His-->Tyr) in the patient's
307 results
Jump to page
Feedback